Target Name: CDCA4P3
NCBI ID: G100420558
Review Report on CDCA4P3 Target / Biomarker Content of Review Report on CDCA4P3 Target / Biomarker
CDCA4P3
Other Name(s): cell division cycle associated 4 pseudogene 3 | Cell division cycle associated 4 pseudogene 3

Unlocking the Potential of CDCA4P3: A drug Target and Biomarker

CDCA4P3, a novel gene encoding a protein with potential as a drug target and biomarker, has been identified and characterized. This protein is expressed in various tissues and cellular types, including brain, heart, liver, and cancer cells. It plays a critical role in cell signaling, DNA repair, and cellular apoptosis, which makes it an attractive target for the development of new pharmaceuticals. In this article, we will explore the potential of CDCA4P3 as a drug target and biomarker, and discuss its clinical implications.

Potential Drug Target

CDCA4P3 has been identified as a potential drug target due to its unique structure and various cellular functions. One of its unique features is its ability to interact with various protein substrates, including histone modifications and non-histone modifications. This interaction suggests that CDCA4P3 could be a useful target for drugs that target modifiers of chromatin structure, such as histone deacetylases (HDACs) and DNA methyltransferases (DNMTs).

In addition to its interaction with protein substrates, CDCA4P3 has been shown to play a critical role in the regulation of cellular apoptosis. Apoptosis is a natural cellular death process that is regulated by various signaling pathways. CDCA4P3 has been shown to regulate the execution of apoptotic programs in various cellular types, including cancer cells. This suggests that CDCA4P3 could be a useful target for drugs that target cellular apoptosis, such as inhibitors of the pro-apoptotic transcription factor, p53.

Potential Biomarker

CDCA4P3 has also been identified as a potential biomarker for various diseases, including cancer. Its unique expression patterns in different tissues and cellular types make it an attractive target for biomarker research. For example, studies have shown that CDCA4P3 is overexpressed in various cancer types, including breast, ovarian, and colorectal cancer. This suggests that CDCA4P3 could be a useful biomarker for these diseases and could help diagnose and monitor the progression of these diseases.

CDCA4P3 has also been shown to be involved in various signaling pathways, including the PI3K/Akt signaling pathway. This pathway is involved in the regulation of cellular signaling and is a potential target for drugs that target signaling pathways involved in cancer development.

Clinical Implications

The identification of CDCA4P3 as a potential drug target and biomarker has significant clinical implications. Its potential as a drug target suggests that drugs targeting its interaction with protein substrates, such as HDACs and DNMTs, could be effective in treating various diseases, including cancer. Additionally, its potential as a biomarker suggests that it could be used to monitor the progression of diseases and detect early changes in disease.

In conclusion, CDCA4P3 is a novel gene that has been identified and characterized. Its unique structure and various cellular functions make it an attractive target for the development of new pharmaceuticals and biomarkers. Further research is needed to fully understand its potential as a drug target and biomarker, and its clinical implications.

Protein Name: Cell Division Cycle Associated 4 Pseudogene 3

The "CDCA4P3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CDCA4P3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

CDCA5 | CDCA7 | CDCA7L | CDCA8 | CDCP1 | CDCP2 | CDH1 | CDH10 | CDH11 | CDH12 | CDH13 | CDH13-AS2 | CDH15 | CDH16 | CDH17 | CDH18 | CDH19 | CDH2 | CDH20 | CDH22 | CDH23 | CDH24 | CDH26 | CDH3 | CDH4 | CDH5 | CDH6 | CDH7 | CDH8 | CDH9 | CDHR1 | CDHR18P | CDHR2 | CDHR3 | CDHR4 | CDHR5 | CDIN1 | CDIP1 | CDIPT | CDIPTOSP | CDK1 | CDK10 | CDK11A | CDK11B | CDK12 | CDK13 | CDK14 | CDK15 | CDK16 | CDK17 | CDK18 | CDK19 | CDK2 | CDK20 | CDK2AP1 | CDK2AP2 | CDK2AP2P2 | CDK2AP2P3 | CDK3 | CDK4 | CDK5 | CDK5R1 | CDK5R2 | CDK5RAP1 | CDK5RAP2 | CDK5RAP3 | CDK6 | CDK6-AS1 | CDK7 | CDK8 | CDK9 | CDKAL1 | CDKL1 | CDKL2 | CDKL3 | CDKL4 | CDKL5 | CDKN1A | CDKN1B | CDKN1C | CDKN2A | CDKN2A-DT | CDKN2AIP | CDKN2AIPNL | CDKN2AIPNLP1 | CDKN2B | CDKN2B-AS1 | CDKN2C | CDKN2D | CDKN3 | CDNF | CDO1 | CDON | CDPF1 | CDR1 | CDR2 | CDR2L | CDRT15 | CDRT15L2 | CDRT4